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Background: Amyotrophic lateral sclerosis (ALS) is an incurable motor neuron degenerative disease which onset
and course may be affected by concurrent diabetes mellitus (DM). We performed a systematic review to assess the
effect of DM/dysglycemic states on ALS.
Methods: We searched PubMed MEDLINE, from inception to March 2013 for original articles published in English
and in French languages on DM (and related states) and ALS. We made no restriction per study designs.
Results: Seven studies/1410 citations (5 case–control and 2 cross-sectional) were included in the final selection. The
number of participants with ALS ranged from 18 to 2371. The outcome of interest was ALS and DM/dysglycemic
states respectively in three and two case control-studies. DM/impaired glucose tolerance status did not affect
disease progression, survival, disease severity and disease duration in ALS participants but ALS participants with
DM were found to be older in one study. DM/IGT prevalence was similar in both ALS and non ALS participants.
This review was limited by the absence of prospective cohort studies and the heterogeneity in ALS and DM
diagnosis criteria.
Conclusions: This systematic review suggests that evidences for the association of ALS and DM are rather limited
and derived from cross-sectional studies. Prospective studies supplemented by ALS registries and animal studies are
needed to better understand the relationship between both conditions.Background
Diabetes mellitus (DM) is a common condition affecting
347 million people worldwide [1]. It is associated with
complications such as renal failure, coronary heart disease,
stroke, limb amputation and peripheral neuropathies. Neu-
ropathies are the most common complications of DM, af-
fecting up to 50% of diabetic patients [2,3]. The deleterious
effect of diabetes on peripheral nerves results from the
interplay of defects in metabolic and vascular pathways
alongside oxidative stress [4]. Furthermore, diabetes melli-
tus may increase peripheral nerve susceptibility to a wide
range of physical and metabolic agents or even accelerate
other disease processes affecting peripheral nerves. Put to-
gether, these epidemiological and mechanistic evidences
suggest that DM may play a role in both initiation and pro-
gression of peripheral nerve injuries in a wide variety of* Correspondence: apkengne@yahoo.com
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unless otherwise stated.pathological conditions. Those conditions include diseases
with worse prognosis such as amyotrophic lateral sclerosis
(ALS). ALS remains an incurable disease and about fifty
percent of those affected will die within 3 years from symp-
toms onset. Although ALS has been described since over a
century, the exact mechanistic pathways leading to the
progressive degeneration of motor neuron remain incom-
pletely understood [5]. The current pathophysiologic con-
ception is that of an interplay of genetic factors (multiple
genes), developmental, environmental and age-related fac-
tors leading to pathological changes and ultimately loss of
motor neurons [6]. Characterising the effects of diabetes
mellitus on ALS occurrence has the potential of improving
the understanding of ALS pathology and opening new
therapeutic avenues.
We aim to conduct a systematic review of published
evidence on the association between diabetes mellitus
and amyotrophic lateral sclerosis.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Data sources and strategies
We searched PubMed MEDLINE, from inception to
March 2013 for articles published in English and French
languages on diabetes (and related states including glucose
intolerance, hyperinsulinemia) and the risk of amyotrophic
lateral sclerosis. We included the term “fronto-temporal
dementia” (FTD) in the search strategy as there are com-
pelling evidence to suggest that FTD and ALS are clinical
expressions of the same disease spectrum [5].
Search strategy included the following terms: ("Diabetes"
OR "Diabetes mellitus" OR “Pre-diabetes” OR “Prediabe-
tes” OR “Glucose intolerance” OR “Hyperinsulinemia” OR
“Hyper-insulinemia” OR “hyperglycemia”) AND (“neuro-
degeneration” OR “neurodegenerative diseases” OR “neu-
rodegenerative disorders” OR “fronto-temporal dementia”
OR “FTD” OR “amyotrophic lateral sclerosis” OR “ALS”
OR “motor neuron disease” OR “Charcot disease” OR
“Lou Gehrig disease” OR "frontotemporal lobe dementia")
NOT ("animal"). In addition, we manually searched the
reference lists of eligible articles and relevant reviews, and
traced studies that had cited them through the ISI Web of
science to identify additional published and unpublished
data. Two evaluators (AL and APK) independently identi-
fied articles and sequentially screened them for possible
inclusion. Eligible articles had to report on diabetes and its
association/impact on ALS in human subjects. We made
no restriction by study design, thus case-series, hospital-
based and population-based studies were considered for
inclusion. Disagreements were solved by consensus.
Data extraction
Two investigators (AL and APK) independently con-
ducted data extraction and quality assessment. From
each study, we extracted data on study setting, study de-
sign, study population characteristics, diagnostic criteria
for ALS and diabetes mellitus/pre-diabetes states, meas-
ure of disease (ALS and diabetes mellitus) occurrence
(incidence/prevalence) and measure of association be-
tween ALS and diabetes mellitus (Odd ratio and Relative
risk).
Data synthesis
Given the wide range of measures of association be-
tween DM/pre-diabetes and ALS across studies, as well
as the variety of study designs, we opted to conduct a
narrative analysis without a formal meta-analysis.
Results
Figure 1 describes the study selection process. Of the
1410 articles retrieved, 49 abstracts were selected for in-
depth evaluation (with most articles being excluded for
not reporting on ALS but rather on other neurodegener-
ative diseases mainly dementia and Parkinson’s disease)and 25 full texts were reviewed, of which 7 were included
in the final selection. Descriptive data and main results are
summarized in Table 1. Five were case–control and two
were cross-sectional studies. All the seven studies were
conducted in western countries including 4 in the USA, 1
in France, Romania and Finland each. The overall study
size varies from 18 to 2371 participants with ALS. Diagno-
sis of ALS was based on EL Escorial criteria in 3 studies
[7-9], on clinical criteria only in one study [10], on the
combination of clinical and electromyographic (EMG) cri-
teria in one study [11]; and it was not reported in two
studies [12,13]. Likewise the diagnosis of diabetes mellitus
and impaired glucose tolerance varies across studies. Two
studies used the WHO 1997 criteria [8,9], one study use
the United states public health service and the national
diabetes data group criteria [12], while diagnosis criteria
for diabetes mellitus and dysglycemia were not provided
in 3 studies.
Case control studies
In three studies, the outcome of interest was related to
ALS [7-9]; these studies reported on the association be-
tween diabetes mellitus/IGT status in ALS and the rate
of progression (2 studies), survival rate (2 studies), age of
onset (1 study), disease duration (1 study) and disease
severity (1 study). In two other studies [11,13], the rate
of diabetes mellitus/IGT was compared between ALS
and non ALS participants. DM/IGT status did not affect
disease progression, survival, disease severity and disease
duration in ALS participants but ALS participants with
DM were found to be older in one study. DM/IGT
prevalence was similar in both ALS and non ALS
participants.
Cross-sectional studies
Two cross-sectional studies reported a prevalence of
IGT/DM ranging from 50 to 56% among ALS partici-
pants [10,12]. In one study, the authors reported that
IGT/DM prevalence was higher in ALS compared to the
general population in the same region.
Discussion
According to this systematic review, diabetes mellitus
and dysglycemia appear to be more frequent among pa-
tients with ALS, but do not seem to affect progression
of disease, disease severity, disease duration and survival
in these patients. Evidences however are either very lim-
ited or mostly derived from single institution, retrospect-
ive, case control and cross-sectional studies. Diagnosis
criteria for ALS and DM/IGT vary substantially across
existing studies, reflecting different time periods where
those studies were conducted. For instance the EL Es-
corial criteria for ALS diagnosis were adopted in the year
2000 while 4 of the 7 included studies were conducted
Figure 1 Flow chart for the study selection.
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been revised a few times in recent decades.
The lack of an association between DM/IGT and ALS
reported in this review seems to be inconsistent with the
known deleterious effect of DM on peripheral nerves.
Similarly, studies looking at the association between ALS
status/survival and metabolic abnormalities closely re-
lated to DM such as obesity and hyperlipidaemia have
yielded conflicting results while in animal models, hy-
permetabolism and mitochondrial dysfunction observed
in ALS suggest a link between energy expenditure, adi-
posity and motor neuron degeneration [14-18]. ALS pa-
tients are usually thin at least at the advanced stage of
the disease possibly, as the result of poor oral intake
(due at least in part to dysphagia) and hypermetabolism,
suggesting interplay between metabolic abnormalities
and ALS onset or progression. A few reasons could ex-
plain this apparent paradox including methodological
issues. Most studies were case control, retrospective,
cross-sectional or single-centre and there were significant
heterogeneity in definitions of exposure and outcomevariables across studies. Furthermore sample sizes were
likely not large enough to reliably capture any sizable asso-
ciation. ALS is a multifactorial diseases whereby genetic,
developmental and environmental factors interplay, result-
ing in loss of both primary and secondary motor neurons
[5]. While the association between DM and ALS has not
been rigorously tested in humans, there are suggestions
from animal models that DM/IGT may interfere with ALS
onset or progression through several mechanisms such as
reactive oxidative species-mediated glucotoxicity or by the
mean of neuro-inflammation. For instance, superoxide
dismutase 1 (SOD1) mutation has been described in sev-
eral families with ALS. SOD1 dysfunction which results in
an increased intra-cellular reactive oxygen species also
plays a major role in diabetes neuropathy. Animal models
of ALS also suggest a role of neuroinflammation in the
events leading to motor neuron loss and disease prog-
ression including microglial dysregulation, an increased
secretion of pro-inflammatory markers such as INF-γ,
TNF-α, a decreased secretion of protective cytokines such
as IL-4, Th1-lymphocytes infiltration and Th-2 depletion
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Case–control N: 274 El Escorial criteria Not provided Rate of progression beta






and Site of onset,
1999-2004 Age: 52y Survival beta coefficient (95% CI)
0.10 (−0.93-3.49) P =0.25
M: 171
Patient with pre-morbid DM









Cases (ALS with pre-morbid
DM):
El Escorial criteria Diabetes mellitus Age of onset in years: ALS with
DM 60.3 vs. ALS without DM:
56.3 (p < 0.02)
Adjustment performed
for possible confounders
including gender and site
of onset
N: 175 Two FBG ≥ 126 mg/dl or two
RBG ≥ 200 mg/dl at or before
the time of ALS diagnosis.
Rate of progression (AALS/
month): ALS with DM 3.58 vs.
ALS without DM: 3.01 (p: NS)
Age: 60y Survival (years): ALS with DM:












Case–control ALS: El Escorial criteria 75 g OGTT Prevalence of IGT in ALS vs.
control (33% vs. 9.5% p =0.13)
OGTT compared between
ALS patients and controls.
N: 21 (including 7 with IGT) DM: FPG > 7.0 mmol/l or the
2-h post-load blood glucose
concentration > 11.0 mmol/l.
Disease duration ALS with IGT
vs. ALS without IGT (17 months
vs. 20 months, p = 0.62),
No adjustment performed
for possible confounders
with IGT vs. ALS without
IGT (17 months vs.
20 months, p = 0.62),
Age: 53y IFPG: FPG between 6.1 and
7.0 mmol/l.
ALSFRS ALS with IGT
35 months vs. ALS without IGT



















Table 1 Features of studies included in the final review (Continued)
M: 86% IGT: FPG < 7.0 mmol/l and
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Not provided Abnormal OGTT: 50%










N: 34 participants with ALS NA USPHS criteria/100 g glucose
load:
56% of ALS patient had an IGT
or DM
Authors reported that the
frequency of IGT and DM
in ALS participants was
higher than in other Asian
pacific regions and USA








Case–control Cases: Clinical and ENMG signs
of lower motor neuron
disease. Signs of upper
motor neuron disease
could be present
Diabetes: FPG of ≥140 mg/dL
(7.8 mmol/L) or a 2-hour PG≥
200 mg/dL in an OGTT
Diabetes: No adjustment for
possible confounders
N: 21 IGT: FPG <7.8 mmol/l, PG-1 h
>11.1 mmol/l, PG-2 h
7.8-11.0 mmol/l)
Case: 5%
Age: 59y PG-1 h >11.1 mmol/l, PG-2 h
7.8-11.0 mmol/l)
Control: 10%
M: 14 OR = 0.45 (95% CI: 0.03-8.02)
Control Abnormal OGTT:
N: 10 Case: 19%
Age: 61y Control: 20%




























N: 45 NA Not provided “Diabetes as
diagnosed and treated by
physicians”
Diabetes: No adjustment for
possible confounders






ALS: Amyotrophic lateral sclerosis, DM: Diabetes mellitus, N: sample size, M: male sex, 95% CI: 95% confidence interval, BMI: Body mass index, FBG: Fasting blood glucose, RBG: Random blood glucose, FPG: Fasting
plasma glucose, OGTT: Oral glucose tolerance test, IGT: Impaired glucose tolerance test, IFPG: Impaired fasting plasma glucose, PG: Plasma glucose, ENMG: Electroneuromyography, ALSFRS: Amyotrophic lateral sclerosis
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and that it precisely induces the same metabolic abnor-
malities support the hypothetic role of diabetes in the
pathogenesis and progression of ALS [22-25]. However it
is worth recalling that most animal models have been de-
rived from the transgenic mouse model overexpressing
SOD1 (which is non diabetic but rather lean and hyper-
metabolic) while only 2% of ALS are related to this muta-
tion [5]. Interestingly, more candidates genes including
TDP-43 gene, FUS gene and the most recent and most
common C9orf72 gene expansion, which phenotype is dis-
tinctively different from other forms of ALS have been re-
ported more frequently; but animal models-when they
exist- do not mimic clinical phenotypes of ALS as closely
as SOD1 mouse [5].
While investigating the relationship between DM and
ALS has the potential of shedding light on some patho-
logical and therapeutic aspects of ALS, these efforts may
nevertheless be hindered by several shortcomings. Evi-
dence from such an association would be best derived
from prospective studies; however the short survival rates
among ALS participants would make such a study particu-
larly difficult to conduct. In addition, achieving large sam-
ple size comparable to those of common complex diseases
like DM would be a challenge for a rare disease such as
ALS. Collaborative efforts would hopefully overcome this
specific challenge. Beside the difficulties related to con-
ducting prospective studies, ALS has not received the
same consideration as other neurological diseases which
may explain why after more than a century there are very
few intervention/drugs that alter the clinical course of the
disease. Fortunately, the recent growing interest of the sci-
entific community has led to the development of animal
models-though the complexity of the disease would re-
quire more models- which may contribute to improve
among others, the understanding of the relationship be-
tween DM and ALS. Likewise, ALS registries are import-
ant components of a multi-level strategy and would
include data on diabetes mellitus status. Lastly, criteria for
ALS diagnosis, ALS severity scoring and diabetes mellitus
have changed across years, therefore making comparisons
across studies challenging. There is a need to standardize
current ALS diagnosis criteria which would include mer-
ging data from the most widely used criteria i.e. the El
Escorial and the Airlie House criteria. Likewise, it is sug-
gested that the amyotrophic lateral sclerosis functional rat-
ing scale (the most widely used score for assessing disease
severity and progression in ALS) would not be linear in
early and late stage of disease hence, this should be
accounted for in statistical analysis [26]. New candidate
variables will need to be evaluated. Disease-severity scales
deserve to be revisited and standardized; for instance recent
findings that those with dysexecutive functions progress
more rapidly suggest that a clinical classification based oncognitive function at diagnosis and rate of progression
would be more useful than the traditional upper/lower
motor neuron and site of involvement classification [27].
To the best of our knowledge, this is the first attempt to
systematically summarize data on the association between
ALS and DM. In line with the recent trends, our system-
atic review may increase awareness among ALS scientists
on the need to define subtypes of ALS and probe into
common mechanistic pathways between diabetes mellitus
and ALS. We are well aware of the limitations of our re-
view. First, the wide heterogeneity between studies designs
and outcomes precluded a refined summary of results and
particularly the ability to perform a meta-analysis. Second,
evidences were derived uniquely from cross-sectional
studies and case–control studies therefore, making it im-
possible to establish the sequence of occurrence or an at-
tempt to draw a mechanistic relationship between ALS
and DM. Third, we could not assess publication biases.
Conclusions
In conclusion, this systematic review suggests that evi-
dence for the association of ALS and DM are rather lim-
ited and derived from observational studies. Prospective
studies supplemented by ALS registries and animal studies
are needed to better understand the relationship between
both conditions. Those studies should ideally focus on
common mechanistic pathways between ALS and DM
such as increased intracellular reactive species, mito-
chondrial dysfunctions, inflammation as well as pathways
through which DM may induce neurodegneration in other
parts of the CNS. Such pathways include among other de-
fects in insulin production, insulin resistance and cluster-
ing of cardiovascular risk factors and their neuro-toxic
effects. Findings from these studies may ultimately pave
the way to improving the dread prognosis of ALS.
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